RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL

In FOURIER, the PCSK9i evolocumab (EvoMab) reduced LDL-C & CV risk; CV risk was proportional to achieved LDL-C down to <20 mg/dL. In CANTOS, anti-inflammatory therapy reduced CV risk w/ no change in lipids, highlighting the role of residual inflammation as defined by hsCRP. We explored the efficacy